dc.creatorMORI, R. C. T.
dc.creatorHIRABARA, S. M.
dc.creatorHIRATA, A. E.
dc.creatorOKAMOTO, M. M.
dc.creatorMACHADO, U. F.
dc.date.accessioned2012-10-20T03:17:48Z
dc.date.accessioned2018-07-04T15:34:18Z
dc.date.available2012-10-20T03:17:48Z
dc.date.available2018-07-04T15:34:18Z
dc.date.created2012-10-20T03:17:48Z
dc.date.issued2008
dc.identifierDIABETES OBESITY & METABOLISM, v.10, n.7, p.596-U5, 2008
dc.identifier1462-8902
dc.identifierhttp://producao.usp.br/handle/BDPI/27950
dc.identifier10.1111/j.1463-1326.2008.00870.x
dc.identifierhttp://dx.doi.org/10.1111/j.1463-1326.2008.00870.x
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1624594
dc.description.abstractAim: Glimepiride, a low-potency insulin secretagogue, is as efficient on glycaemic control as other sulphonylureas, suggesting an additional insulin-sensitizer role. The aim of the present study was to confirm the insulin-sensitizer role of glimepiride and to show extra-pancreatic effects of the drug. Methods: Three-month-old monosodium glutamate (MSG)-induced obese insulin-resistant rats were treated (OG) or not treated (O) with glimepiride for 4 weeks and compared with age-matched non-obese rats (C). Insulin sensitivity in whole body, glucose transporter 4 (GLUT4) protein content, glucose uptake and glycogen synthesis in oxidative skeletal muscle and phospho-glycogen synthase kinase (p-GSK3) and glycogen content in liver were analysed. Results: Insulin sensitivity, analysed by the insulin tolerance test, was 30% lower in O than in C rats (p < 0.05), and OG rats recovered this parameter (p < 0.05). In oxidative muscle, glimepiride increased the GLUT4 protein content (50%, p < 0.001) and recovered the obesity-induced reduction (similar to 20%) of the in vitro insulin-stimulated glucose uptake and incorporation into glycogen. In liver, glimepiride increased p-GSK3 (p < 0.01) and glycogen (p < 0.05) contents. Conclusion: The increased GLUT4 protein expression and glucose utilization in oxidative muscle and the increased insulin sensitivity and glycogen storage in liver evidence the insulin-sensitizer effect of glimepiride, which must be important to enable the glimepiride drug to promote an efficient glycaemic control.
dc.languageeng
dc.publisherWILEY-BLACKWELL
dc.relationDiabetes Obesity & Metabolism
dc.rightsCopyright WILEY-BLACKWELL
dc.rightsrestrictedAccess
dc.subjectglimepiride
dc.subjectGLUT4
dc.subjectinsulin resistance
dc.subjectliver
dc.subjectMSG
dc.subjectskeletal muscle
dc.subjectGSK3
dc.titleGlimepiride as insulin sensitizer: increased liver and muscle responses to insulin
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución